Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants
Abstract Co‐administration of clesacostat (acetyl‐CoA carboxylase inhibitor, PF‐05221304) and ervogastat (diacylglycerol O‐acyltransferase inhibitor, PF‐06865571) in laboratory models improved non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) end points and mitigated cle...
Main Authors: | Aarti Sawant‐Basak, Arthur J. Bergman, Jessica Mancuso, Sakambari Tripathy, James R. Gosset, Laure Mendes da Costa, William P. Esler, Roberto A. Calle |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-02-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13687 |
Similar Items
-
The role of DGAT1 and DGAT2 in regulating tumor cell growth and their potential clinical implications
by: Boer Deng, et al.
Published: (2024-03-01) -
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
by: Rita Humeniuk, et al.
Published: (2023-11-01) -
Multilabel Text Classification Using Multilayer DGAT
by: Hui Chen, et al.
Published: (2022-01-01) -
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants
by: Orestis Papasouliotis, et al.
Published: (2022-12-01) -
Functional analysis of alternative castor bean DGAT enzymes
by: Thomaz Stumpf Trenz, et al.
Published: (2022-12-01)